Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients ... about ordering a cost-benefit analysis before making the commitment. Already, West Virginia ...